Request Demo

Last update 08 May 2025

TBL1X

Last update 08 May 2025

Basic Info

Synonyms

EBI, F-box-like/WD repeat-containing protein TBL1X, SMAP55

+ [5]

Introduction

F-box-like protein involved in the recruitment of the ubiquitin/19S proteasome complex to nuclear receptor-regulated transcription units (PubMed:14980219). Plays an essential role in transcription activation mediated by nuclear receptors. Probably acts as integral component of corepressor complexes that mediates the recruitment of the 19S proteasome complex, leading to the subsequent proteasomal degradation of transcription repressor complexes, thereby allowing cofactor exchange (PubMed:21240272).

Drugs associated with TBL1X

Tegatrabetan

Target

TBL1X

Mechanism

TBL1X inhibitors

Active Org.

Ohio State University Comprehensive Cancer Center [+2]

Originator Org.

Iterion Therapeutics, Inc.

Active Indication

Acute Myeloid Leukemia [+9]

Inactive Indication

Aggressive Fibromatosis

Drug Highest PhasePhase 2

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

TD-11

Target

TBL1X

Mechanism

TBL1X inhibitors

Active Org.

The Ohio State University

Originator Org.

The Ohio State University

Active Indication

Diffuse Large B-Cell Lymphoma

Inactive Indication-

Drug Highest PhaseDiscovery

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

Clinical Trials associated with TBL1X

NCT05797805

/ RecruitingPhase 1/2

A Phase 1/2 Exploratory Study of the TBL1 Inhibitor, Tegavivint (BC2059), in Patients With Advanced Hepatocellular Carcinoma

This study will be conducted in 2 parts. The first part is a phase 1 single-agent dose escalation,optimization, and expansion study of tegavivint in patients with advanced HCC after failure of at least one line of prior systemic therapy. In the second part of the study, the combination of tegavivint plus pembrolizumab will be assessed with a limited dose escalation followed by a randomized dose optimization.

Start Date13 Sep 2023

Sponsor / Collaborator

Iterion Therapeutics, Inc.

NCT05755087

/ RecruitingPhase 1IIT

Phase Ib Trial of Tegavivint in Patients with Relapsed/Refractory C-MYC Overexpressing Large B-Cell Lymphoma

This phase I trial tests the safety, side effects, and best dose of tegavivint in treating patients with large b-cell lymphomas that has come back (relapsed) or does not respond to treatment (refractory). Tegavivint may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving tegavivint may help control the disease.

Start Date06 Mar 2023

Sponsor / Collaborator

Ohio State University Comprehensive Cancer Center

NCT04780568

/ RecruitingPhase 1IIT

A Phase Ib Study of AZD9291 (Osimertinib) and BC2059 (Tegavivint) As First-Line Therapy in Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

This phase Ib trial is to find out the best dose, possible benefits and/or side effects of osimertinib and tegavivint as first-line therapy in treating patients with EGFR-mutant non-small cell lung cancer that has spread to other places in the body (metastatic). Osimertinib and tegavivint may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Start Date18 Jan 2022

Sponsor / Collaborator

Ohio State University Comprehensive Cancer Center

100 Clinical Results associated with TBL1X

100 Translational Medicine associated with TBL1X

0 Patents (Medical) associated with TBL1X

118

Literatures (Medical) associated with TBL1X

22 Apr 2025·Blood Advances

Targeting the DNA damage response through TBL1X in mantle cell lymphoma

Article

Author: Hinterschied, Claire ; Singh, Satishkumar ; Alinari, Lapo ; Jindal, Udita ; Leon, Sydney ; Tsyba, Liudmyla ; Barta, Brian ; Jain, Neeraj ; Nishat, Shamama ; Hout, Ian ; Koirala, Shirsha ; Carvajal-Moreno, Jessika ; Chan, Wing Keung ; Baiocchi, Ethan ; Pray, Betsy ; Hanel, Walter ; Sehgal, Lalit ; Baiocchi, Robert A. ; Yalowich, Jack

AbstractMantle cell lymphoma (MCL) is an incurable B-cell lymphoma characterized by significant genomic instability. Patients with MCL who progress on targeted therapies have a short survival; thus, novel therapeutic strategies are urgently needed. Overexpression of transducin β-like protein 1 X-linked (TBL1X) has been documented in several types of cancer and associated with poor prognosis. TBL1X is a critical regulator of multiple oncogenic networks; however, its function in MCL has not been explored. Our data show that, unlike normal B cells, MCL cells express abundant levels of TBL1X and that genetic knockdown of TBL1X and treatment with tegavivint (Iterion), a first-in-class small molecule targeting TBL1X, promote MCL cell death in vitro and in vivo. Moreover, TBL1X controls the stability of key MCL oncogenic drivers, cyclin D1 and RAD51; and targeting TBL1X results in significant DNA damage, cell cycle arrest, and ultimately cell death. Combining tegavivint with poly(adenosine 5′-diphosphate-ribose) polymerase-1/2 inhibitor talazoparib results in synergistic MCL cell death in vitro, and in vivo this combination significantly prolongs the survival of a patient-derived MCL xenograft. Together, our results define the role of TBL1X in maintaining genomic stability in MCL and establish targeting TBL1X as a novel therapeutic strategy for patients with this incurable disease.

01 Jan 2025·Cancer Science

PPM1G‐mediated TBL1X mRNA splicing promotes cell migration in hepatocellular carcinoma

Article

Author: Su, Shu‐Guang ; Shi, Xinyu ; Zhang, Chris Zhiyi ; Hu, Liling ; Zheng, Dandan ; Shi, Fujin ; Liu, Danya ; Zhang, Meifang ; Li, Yuying ; Yuan, Xiaoyi

AbstractThe progression of hepatocellular carcinoma (HCC) is coincident with aberrant splicing of numerous tumor‐related genes. Identification of the tumor‐specific splice variants that facilitate HCC metastasis may provide a more comprehensive insight into the mechanisms of HCC metastasis. Through RNA sequencing and bioinformatic analyses, PPM1G was identified as a biomarker associated with HCC metastasis. Our data mapped a transcriptome‐wide landscape of alternative splicing events modulated by PPM1G in HCC. Notably, we characterized the exon six‐skipping transcript of TBL1X as an onco‐splice variant regulated by PPM1G. Experimental validation revealed the enrichment of TBL1X‐S in response to PPM1G overexpression. Moreover, mRNA stability analyses revealed that PPM1G prolonged the half‐life of the TBL1X‐S transcript. Both PPM1G and TBL1X‐S exhibited metastasis‐promoting phenotypes, with PPM1G‐driven metastasis in HCC being partially dependent on TBL1X‐S. Mechanistically, different TBL1X splice variants showed varying affinities for ZEB1, with TBL1X‐S significantly enhancing ZEB1 activation and repressing CDH1 transcription, potentially accelerating the epithelial‐mesenchymal transition (EMT) process. In conclusion, our study highlights the biological role of PPM1G and TBL1X‐S in tumor metastasis. The PPM1G/TBL1X‐S signaling axis presents a new view for investigating liver cancer metastasis mechanisms.

01 Dec 2024·Journal of Alzheimer’s Disease

Investigating gene expression datasets of hippocampus tissue to discover Alzheimer's disease-associated molecular markers

Article

Author: Thakur, Sonu Chand ; Sajad, Mohd ; Shamsi, Anas ; Prabha, Sneh ; Anjum, Farah ; Hassan, Md Imtaiyaz

Background Alzheimer's disease (AD) is an advancing neurodegenerative disorder distinguished by the formation of amyloid plaques and neurofibrillary tangles in the human brain. Nevertheless, the lack of peripheral biomarkers that can detect the development of AD remains a significant limitation. Objective The main aim of this work was to discover the molecular markers associated with AD. Methods We conducted a comprehensive microarray analysis of gene expression data from hippocampus tissue in AD patients and control samples using three microarray datasets (GSE1297, GSE28146, and GSE29378) collected from Gene Expression Omnibus (GEO). The datasets were pre-processed and normalized, revealing 346 significant genes, 103 of which were upregulated and 243 downregulated. The PPI network of significant genes was constructed to detect the top 50 hub genes, which were then further analyzed using Gene Ontology (GO) terms, Kyoto Encyclopedia of Genes and Genomes pathway (KEGG), and GSEA, revealing 47 key genes involved in AD-related pathways. These key genes were then subjected to feed forward loop (FFL) motif analysis for the prediction of transcriptional factors (TFs) and microRNAs (miRNAs) mediated gene regulatory networks. Results The interaction of AD-associated TFs HNF4A, SPI1, EGR1, STAT3, and MYC and miRNAs hsa-miR-155-5p and hsa-miR-16-5p in the transcriptional and post-transcriptional events of 3 upregulated and 10 downregulated genes: H2AFZ, MCM3, MYO1C, AXIN1, CCND1, ETS2, MYH9, RELA, RHEB, SOCS3, TBL1X, TBP, TXNIP, and YWHAZ, respectively, has been identified. The miRNA/TF-mediated three types of the FFL motifs, i.e., miRNA-FFL, TF-FFL, and composite-FFL, were constructed, and seven common genes among these FFL were identified: CCND1, MYH9, SOCS3, RHEB, MYO1C, TXNIP, AXIN1, and TXNIP. Conclusions These findings may provide insights into the development of potential molecular markers for therapeutic management of AD.

Analysis

Perform a panoramic analysis of this field.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

TBL1X

Basic Info

Related

Analysis